Objective: To examine the efficiency of a 1000 cc intragastric balloon as an aid for weight reduction.
INTRODUCTION
Use of intragastric balloons as part of the therapeutic intervention program for weight reduction is an attractive theoretical approach that has met with technical difficulties. This caused most physicians to currently forego this option in treating obesity [1] . Over the past decade, several types of intragastric balloons were tested and not found to be definitely better than other nonsurgical approaches [2, 3] . The Garren-Edwards balloon, a 200 cc bubble, was found to be associated with serious complications [4] . The 500cc Danish Balloobes Bubble was found to be safe but not more effective than a very low calorie diet with medical and dietary support [5, 6] . The purpose of the present study was to test the hypotheses that a larger volume balloon and/or a longer duration of insertion would be more effective than those previously used, without compromising patient safety. An additional objective of this research was to study the effect of gastric distension on serum Bombesin and Gastrin levels.
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METHODS
Thirty-three morbidly obese patients were admitted to an open trial. Criteria for inclusion in the study were severe obesity, failure at maintaining weight loss from previously attempted noninvasive approaches, and fully informed consent as required by the Helsinki Committee. Severe obesity was defined using the National Health and Nutrition Examination Survey (NHANESII) criteria [7] . Exclusion outpatient basis. Following esophagogastroduodenoscopy the balloon was inserted alongside the endoscope, using a snare device to hold the balloon in place. After inflation of 1000 cc of air, the inflation catheter and endoscope were removed. Removal of balloons was performed by puncturing the balloon with a sclerotherapy needle, and, after deflation, snare removal. Volume stability and positioning was followed by plain film X-rays of the abdomen (see Fig. 1 ).
Hormonal Measurements
There are several reports which have explored the associations and putative roles of peptide hormones and satiety [8] . The best studied are Cholecystokinin, Pancreatic Glucagon and Bombesin. Gastric dilatation causes gastric secretion in the rat, through activation of Bombesin neurons [9] . In the human, variable effects have been reported [10] [11] [12] . The 
influence of Bombesin on
Gastrin release has been demonstrated in various situations [13] . We attempted to determine whether chronic gastric distension as caused by a
Balloon Qualities
The balloon used was produced by the Tremco Company (Nethanya, Israel) from a mixture of synthetic thermostatic elastomeres, enabling the 1000 cc volume expansion without loss of stability.
It had a smooth surface with radio-opaque surface markers. The procedure was performed on an FIGURE 1000 cc air-filled balloon in the stomach. After the short-lived initial weight loss most patients ceased to lose weight and then proceeded to regain the weight initially -lost (see Table I and Fig. 2 ). Mean weight lost after six months was 6 kg (range 0-22 kg). A frequent sensation experienced by patients was abdominal discomfort relieved by eating, and it was thus difficult for them to skip or reduce the size of meals.
The results of the peptide hormonal studies were as follows: prior to insertion of the balloon Gastrin level (pg/ml) was 46.3 SD 2.8. After six months, prior to withdrawal, the Gastrin level was 41.2 SD 2.2. This difference showed a nonsignificant trend towards decreased gastrin distension. Bombesin level prior to insertion was 39.4 SD 5.9pg/ml, and six months later, before balloon withdrawal was 16.9 SD 3.4 pg/ml. This difference was statistically significant, p < 0.001 (see Table II ).
We found no correlation between Bombesin level and the weight of the patients. 
DISCUSSION
Mathus-Vliegen and Tytgat [5] in 1990 asked the question: "Would a higher-volume and longerlasting balloon promote a greater weight loss or prolong adherence and compliance to treatment?" The present study was designed specifically to answer this important question. The balloon was designed to allow for a 1000cc volume and was left in place for six months, as compared to recommended usage of the Garren-Edwards balloon, using 200cc for 12 weeks. The balloon was unique in being air-filled rather than fluid-filled.
Because our focus was to examine the result of a high volume balloon, we chose to use a constant volume of air, rather then adjust volume to the patient, as had been suggested at the Tarpon Springs Comprehensive Workshop [4] . Our balloon did not produce significant long-term weight loss. Our patients came to twice-monthly dietician and weekly physician interviews, but continued to experience hunger and discomfort which was relieved by eating. We could not establish whether this discomfort and cramping were the result of the balloon, a possible side effect, or from hunger related to the eating habits of the patients. Patients indicated that their hunger returned to the level it had been at before the balloon insertion, only 2-3 weeks after the balloon was inserted. Dietary assessments by physicians and dieticians, including use of substitutions and considerable encouragement and support, aiming for 1000-1200kcal/day diets, left us with the impression that patients eating habits were unaffected by the balloon after the initial period of adaptation to its effect.
We found the level of Bombesin but not of In the National Institutes of Health Consensus Development Conference Statement, specific needs were identified in the research for more effective alternate forms of weight reduction therapy [15] . Until the physiology of morbid obesity is better understood and appropriate interventions developed, our efforts may best be directed towards elucidating the pathophysiology of obesity, and meanwhile towards behavior modification and other noninvasive and invasive approaches. One survey of 50 experts significantly viewed the potential for anorectic drugs in the next ten years as considerably better than at present [16] .
Our patients did not experience weight loss for a significant duration. These patients were self selected; they were highly motivated, severely obese patients who had all failed in many previous attempts to lose weight by other means.
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CONCLUSIONS
We conclude that neither intragastric balloon size nor the duration of use of the balloon could be demonstrated to be critical factors in determining the effectiveness of a weight loss program utilizing this modality. The reduction in the serum level of Bombesin, but not of serum Gastrin, following six months of balloon distension suggest that these hormones may be involved in a new homeostasis which may prevent feeling satiety despite having a small available gastric volume. This may be the cause for failure of various trials aimed at reducing intake by causing early satiety.
